P0663: Efficacy and safety of risankizumab therapy in Chinese patients with moderately to severely active crohn’s diseaseECCO'25Year: 2025
Authors: Gao, X.(1)*;Cao, Q.(2);Ran, Z.H.(3);Chen, Y.X.(4);Chen, Y.(5);Wen, Z.H.(6);Liu, D.L.(7);Ding, J.(8);Zhong, J.(9);Liu, F.(10);Sha, W.H.(11);An, P.(12);Wang, B.M.(13);Hu, L.X.(14);
(1)The Sixth Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(2)Sir Run Run Shaw Hospital- Medical School Zhejiang University, Department of Gastroenterology, Hangzhou, China;(3)Zhou Pu Hospital,Shanghai University of Medicine & Health Sciences, Department of Gastroenterology, Shanghai, China;(4)The First Affiliated Hospital of Nanchang University, Department of Gastroenterology, Nanchang, China;(5)The second Affiliated Hospital of Zhejiang University, Department of Gastroenterology, Hangzhou, China;(6)West China Hospital- Sichuan University, Department of Gastroenterology, Chengdu, China;(7)The Second Xiangya Hospital- Central South University, Department of Gastroenterology, Changsha, China;(8)Jinhua Hospital of Zhejiang University School of Medicine, Department of Gastroenterology, Jinhua, China;(9)Ruijin Hospital- Shanghai Jiaotong University School of Medicine, Department of Gastroenterology, Shanghai, China;(10)Shanghai East Hospital- Tongji University School of Medicine, Department of Gastroenterology, Shanghai, China;(11)Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences- Southern Medical University, Department of Gastroenterology, Guangzhou 510080, China;(12)Renmin Hospital of Wuhan University, Department of Gastroenterology, Wuhan, China;(13)General Hospital-Tianjin Medical University, Department of Gastroenterology and Hepatology, Tianjin, China;(14)Abbvie, medical, Shanghai, China;
1.D’Haens G, et al. Lancet. 2022;399:2015–30. 2.Ferrante M, et al. Lancet. 2022;399:2031–46.
P0664: Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDAECCO'25Year: 2025
Authors: Chaparro, M.(1)*;Hermida, S.(1);Zabalza San Martín, L.(2);Tosca Cuquerella, J.(3); de Castro, L.(4); Larrubia Domínguez, C.(5);Rodríguez-Lago, I.(6);Reygosa Castro, C.(7);Varela Trastoy, P.(8); Gargallo-Puyuelo, C.J.(9);Ripoll Abadía, P.(10);Ruiz-Cerulla, A.(11);Barreiro-de Acosta, M.(12);de Francisco, R.(13);Gutiérrez, A.(14);Jiménez, N.(15);Pajares Villarroya, R.(16);Bujanda, L.(17);Trapero Martínez, A.M.(18);Arias García, L.(19);Camargo Camero, R.(20);Calafat, M.(21);Diz-Lois Palomares, M.T.(22);Robledo Andrés, P.(23);Sampedro, M.J.(24);Ber Nieto, Y.(25);Bermejo, F.(26);Calvo Moya, M.(27);Casanova, M.J.(1);Ceballos, D.(28);Martín-Rodríguez, D.(29);Mesonero, F.(30);Zabana, Y.(31);Sanjosé Crespo, A.(32);Sierra-Ausín, M.(33);Caballol, B.(34);Curieses Luengo, M.(35);Giordano, A.(36);Domènech, E.(21); Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario de Navarra and Instituto de Investigación Sanitaria de Navarra IdiSNA, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Clínico Universitario de Valencia, IBD Unit, Valencia, Spain;(4)Complexo Hospitalario Universitario de Vigo CHUVI- Sergas. Grupo de Investigación en Patología Digestiva- Instituto de Investigación Sanitaria Galicia Sur IIS Galicia Sur, Gastroenterology Unit, Vigo, Spain;(5)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(6)Hospital Universitario de Galdakao- Biobizkaia Health Research Institute, Gastroenterology Unit, Galdakao, Spain;(7)Complejo Hospitalario Universitario de Canarias CHUC, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(8)Hospital Universitario de Cabueñes- CAHU, Gastroenterology Unit, Gijón, Spain;(9)Hospital Clínico Universitario “Lozano Blesa”- IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(10)Hospital Universitari i Politécnic la Fe, Gastroenterology Unit, Valencia, Spain;(11)Hospital Universitari de Bellvitge and Institut d’Investigació Biomédica de Bellvitge, Gastroenterology Unit, L’Hospitalet de Llobregat, Spain;(12)Complexo Hospitalario Universitario de Santiago de Compostela and Santiago de Compostela Health Research Institute, Gastroenterology Unit, Santiago de Compostela, Spain;(13)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(14)Hospital General Universitario Dr Balmis de Alicante- ISABIAL and CIBEREHD, Gastroenterology Unit, Alicante, Spain;(15)Hospital General Universitario Elche, Gastroenterology Unit, Elche, Spain;(16)Hospital Universitario Infanta Sofía. Facultad de Medicina- Universidad Europea de Madrid, Gastroenterology Unit, Madrid, Spain;(17)Biogipuzkoa Health Research Institute- CIBEREHD and Universidad del País Vasco UPV/EHU, Gastroenterology Unit, San Sebastián, Spain;(18)Hospital Universitario de Jaén, Gastroenterology Unit, Jaén, Spain;(19)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(20)Hospital Virgen de la Victoria, Gastroenterology Unit, Málaga, Spain;(21)Hospital Universitari Germans Trias i Pujol and CIBEREHD, Gastroenterology Unit, Badalona, Spain;(22)Complejo Hospitalario Universitario A Coruña, Gastroenterology Unit, A Coruña, Spain;(23)Hospital Universitario de Cáceres, Gastroenterology Unit, Cáceres, Spain;(24)Hospital de Mataró, Gastroenterology Unit, Mataró, Spain;(25)Hospital San Jorge, Gastroenterology Unit, Huesca, Spain;(26)Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain;(27)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(28)Hospital Universitario de Gran Canaria Dr. Negrín and HUGCDN, Gastroenterology Unit, Las Palmas de Gran Canaria, Spain;(29)Hospital Universitario Infanta Cristina, Gastroenterology Unit, Parla, Spain;(30)Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain;(31)Hospital Universitari Mútua Terrassa and CIBEREHD, Gastroenterology Unit, Terrassa, Spain;(32)Hospital Universitario Río Hortega, Gastroenterology Unit, Valladolid, Spain;(33)Complejo Asistencial Universitario de León, Gastroenterology Unit, León, Spain;(34)Hospital Clínic Barcelona. Fundació Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and CIBEREHD, Gastroenterology Unit, Barcelona, Spain;(35)Hospital Santos Reyes, Gastroenterology Unit, Aranda de Duero, Spain;(36)Hospital de la Santa Creu i Sant Pau IR-Sant Pau, Gastroenterology Unit, Barcelona, Spain; on behalf of the U-REAL-UC study group of ENEIDA
P0665: Long-term efficacy and dose intensification of ustekinumab in achieving clinical, laboratory, and endoscopic remission in Crohn’s disease.ECCO'25Year: 2025
Authors: Dussias, N.(1)*;Melotti, L.(2);Vanigli, N.(1);Gionchetti, P.(1);Rizzello, F.(1);
(1)University of Bologna, Dept of Medical and Surgical Sciences, Bologna, Italy;(2)IRCCS Azienda Ospedaliero Universitaria di Bologna- Policlinico Sant'Orsola-Malpighi, Dept of Medical and Surgical Sciences, Bologna, Italy;
P0666: Early symptom improvements predict later clinical response and remission at week 12 for patients with ulcerative colitis treated with mirikizumab in the LUCENT-1 studyECCO'25Year: 2025
Authors: Schreiber , S.W.(1);Issacs , K.(2);Zhu , B.(3);Wu , J.(3);Keohane , A.(3);Redondo , I.(3);Owen , C.(3)*;Navabi , S.(4);
(1)Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany;(2)University of North Carolina, Medicine, North Carolina, United States;(3)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(4)United Medical Doctors, Gastroenterology, Fountain Valley, United States;
1. D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis [published correction appears in N Engl J Med. 2023 Aug 24;389(8):772. doi: 10.1056/NEJMx230004]. N Engl J Med. 2023;388(26):2444-2455. doi:10.1056/NEJMoa2207940
2. Sands BE, D'Haens G, Clemow DB, et al. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis. Published online October 25, 2024. doi:10.1093/ibd/izae253
P0667: Therapeutic Optimization of Biologic Therapy in Ulcerative Colitis: A Retrospective Analysis of Endoscopic and Biomarker OutcomesECCO'25Year: 2025
Authors: Bezzio, C.(1,2);Bertin, L.(1,3)*;Ranucci, L.G.(1);Marconcini, G.(1);Busacca, A.(1);Dal Buono, A.(1);Gabbiadini, R.(1);Loy, L.(1);Armuzzi, A.(1,2);
(1)IRCCS Humanitas Research Hospital, Gastroenterology Department- IBD Unit, Rozzano, Italy;(2)Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy;(3)Azienda Ospedale Università Padova, Gastroenterology Unit- Department of Surgery- Oncology and Gastroenterology, Padova, Italy;
1. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. PMID: 33359090.
2. Shah SC, Colombel JF, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016 Sep;14(9):1245-1255.e8. doi: 10.1016/j.cgh.2016.01.015. Epub 2016 Jan 30. PMID: 26829025.
P0668: Is there a "Weekend Effect" on clinical outcomes in acute severe ulcerative colitis? A single centre retrospective analysisECCO'25Year: 2025
Authors: Mohamedrashed, M.(1);Yogakanthi, S.(1);xu, C.(1);Bartlett, R.(1);Chew, M.(1);Nedumannil, L.(1);Lucas, S.(1);Chauhan, A.(1);Lewis, D.(1);Kashkooli, S.(1);Garg, M.(1)*;
(1)Northern Health, Gastroenterology, Melbourne, Australia;
P0669: Safety of intravenous and subcutaneous guselkumab induction administration: Results from the GALAXI and GRAVITI studies in participants with Crohn’s DiseaseECCO'25Year: 2025
Authors: Danese, S.(1)*;Sands, B.E.(2);Afzali, A.(3);Hisamatsu, T.(4);Armuzzi, A.(5);Wolf, D.(6);Duvall, G.(7);Van Rampelbergh, R.(8);Olurinde, M.(9);Terry, N.A.(9);Yee, J.(9);Li, H.(9);Rosas Ballina, M.(10);D'Haens, G.(11);Rubin, D.T.(12);Panaccione, R.(13);
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milano, Italy;(2)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)University of Cincinnati- College of Medicine, Division of Digestive Diseases, Cincinnati, United States;(4)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(5)Humanitas Research Hospital- Humanitas University, IBD Center, Milan, Italy;(6)Atlanta Gastroenterology Associates, Gastroenterology, Atlanta, United States;(7)Tyler Research Institute- LLC, Gastroenterology, Tyler, United States;(8)Janssen Research & Development, Immunology, Antwerp, Belgium;(9)Janssen Research & Development, Immunology, Spring House, United States;(10)Actelion Research & Development, Immunology, Allschwil, Switzerland;(11)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;(12)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(13)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;
P0670: Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn’s disease: Results from the phase 3 GRAVITI studyECCO'25Year: 2025
Authors: Hart, A.(1)*;Hisamatsu, T.(2);Steinwurz, F.(3);D’Haens, G.(4);Liu, W.(5);Olurinde, M.(6);Ngqawa, P.(6);Yang, Z.(6);Merrall, E.(7);Terry, N.A.(6);Panaccione, R.(8);Sands, B.E.(9);
(1)London North-West University Healthcare NHS Trust, Gastroenterology, London, United Kingdom;(2)Kyorin University, Gastroenterology, Tokyo, Japan;(3)Hospital Israelita Albert Einstein, Gastroenterology, São Paulo, Brazil;(4)Amsterdam University Medical Centers, Gastroenterology, Amsterdam, The Netherlands;(5)The Second People's Hospital of Changzhou- The Third Affiliated Hospital of Nanjing Medical University, Gastroenterology, Changzhou, China;(6)Janssen Research & Development- LLC, Immunology, Spring House, United States;(7)Janssen Vaccines and Prevention BV, Immunology, Leiden, The Netherlands;(8)University of Calgary, Gastroenterology, Calgary, Canada;(9)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
1) Panaccione R, Hart A, Steinwurz F, et al. Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results through week 48 from the phase 3 GRAVITI study. Presented at American College of Gastroenterology 2024.
P0671: Supporting vedolizumab treatment throughout pregnancy: Insights from a population pharmacokinetic modelECCO'25Year: 2025
Authors: Duvnjak, Z.(1,2)*;Steenholdt, C.(3,4);Skejø, C.(5);Baunwall, S.M.D.(5);Widigson, E.S.K.(1,2);Korgaard, J.(5);Klassen, R.A.(6);Bolstad, N.(6);Kjeldsen, J.(4);Poulsen, A.(7,8);Kievit, L.(9);Larsen, L.(10,11);Munkholm, P.(12);Svenningsen, L.(13);Haderslev, K.V.(8);Wildt, S.(14,15);Vind, I.(14);Kelsen, J.(5,16);Abrantes, J.A.(17);Michelet, R.(1);Huisinga, W.(2,18);Kloft, C.(1,2);Julsgaard, M.(5,16);
(1)Freie Universität Berlin, Department of Clinical Pharmacy and Biochemistry- Institute of Pharmacy, Berlin, Germany;(2)PharMetrX, Graduate Research Training program, Berlin/Potsdam, Germany;(3)Copenhagen University Hospital Herlev, Department of Gastroenterology, Copenhagen, Denmark;(4)Odense University Hospital, Department of Medical Gastrointestinal Diseases, Odense, Denmark;(5)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(6)Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway;(7)Bispebjerg University Hospital, Digestive Disease Center, Copenhagen, Denmark;(8)University Hospital of Copenhagen- Rigshospitalet, Department of Digestive Diseases- Transplantation and General Surgery- Section for IBD, Copenhagen, Denmark;(9)Gødstrup Hospital, Department of Medicine, Gjødstrup, Denmark;(10)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(11)Aalborg University, Center for Molecular Prediction of Inflammatory Bowel Disease [PREDICT]- Department of Clinical Medicine, Copenhagen, Denmark;(12)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(13)Horsens Regional Hospital, Department of Internal Medicine, Horsens, Denmark;(14)Hvidovre University Hospital, Unit of Medical and Surgical Gastroenterology, Hvidovre, Denmark;(15)Koege Hospital- University of Copenhagen, Department of Gastroenterology, Koege, Denmark;(16)Aarhus University, Institute of Clinical Medicine- Health, Aarhus, Denmark;(17)Roche Innovation Center Basel, Roche Pharma Research and Early Development- Pharmaceutical Sciences, Basel, Switzerland;(18)Universität Potsdam, Institute of Mathematics, Potsdam, Germany;
1. Prentice R, Flanagan E, Wright EK, et al. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero. Clin Gastroenterol Hepatol. Published online March 2024:S1542356524002520. doi:10.1016/j.cgh.2024.02.0252.
2. Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. J Crohns Colitis. 2023;17(1):1-27. doi:10.1093/ecco-jcc/jjac1153.
3. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188-202. doi:10.1111/apt.132434.
4. Verstockt B, Mertens E, Dreesen E, et al. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. J Crohns Colitis. 2020;14(3):332-341. doi:10.1093/ecco-jcc/jjz151.
P0672: Comparative Efficacy of Medical Therapies in Reducing the Risk of Post Operative Recurrence in Crohn’s Disease (PORCD): A Systematic Review and Network Meta-analysisECCO'25Year: 2025
Authors: Shehab, M.(1)*;Alrashed , F.(2);Alrashed, O.(3);Alyousefi, R.(3);Zoughlami, A.(4);Lakatos, P.L.(5);Siddharth , S.(6);Matthieu , A.(7);Miguel, R.(8);Bessissow, T.(5);
(1)Mubarak Alkabeer University Hospital, Department of Internal Medicine-, Jabriya, Kuwait;(2)Kuwait University, Pharmacy practice, Jabriya, Kuwait;(3)Mubarak Alkabeer University Hospital, Department of Internal Medicine, Jabriya, Kuwait;(4)McGill University Health Center, Department of Medicine-, Montreal, Canada;(5)McGill University Health Center, Department of Medicine, Montreal, Canada;(6)University of California, Department of Medicine, San Diego, United States;(7)Hôpital Saint-Louis, Gastroenterology Department-, Paris, France;(8)Cleveland Clinic, Digestive Disease Institute and Department of Gastroenterology, Cleveland, United States;
1. Spinelli A, Sacchi M, Fiorino G, Danese S, Montorsi M. Risk of postoperative recurrence and postoperative management of Crohn's disease. World J Gastroenterol. 2011;17(27):3213-3219. doi:10.3748/wjg.v17.i27.3213
2. Fasulo E, D'Amico F, Osorio L, et al. The Management of Postoperative Recurrence in Crohn's Disease. J Clin Med. 2023;13(1):119. Published 2023 Dec 25. doi:10.3390/jcm13010119
P0673: Proactive switching to subcutaneous vedolizumab in Inflammatory bowel disease correlates with raised trough levels and confers a clinical benefit: a real-world experience.ECCO'25Year: 2025
Authors: Fouda, S.(1)*;Newby, Y.(1);Zafar, S.(1);Bouri, S.(1);Mohamed, Z.(1);Johnston, E.(1);
(1)West Middlesex University Hospital, Gastroenterology, London, United Kingdom;
1. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16:2–17. doi: 10.1093/ecco-jcc/jjab1782
2. Lim SH, Gros B, Sharma E, et al. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom. Inflamm Bowel Dis. 2024;30:1284–94. doi: 10.1093/ibd/izad1663
3. Bergqvist V, Holmgren J, Klintman D, et al. Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55:1389–401. doi: 10.1111/apt.16927
P0674: Development of a screening tool to address dietary habits in persons with IBD in GermanyECCO'25Year: 2025
Authors: Wilke, E.L.(1)*;Wiestler, M.(2);Middelhoff, M.(3);Schult-Hannemann, D.(3);Knoedler, L.L.(1);Ebert, M.P.(1);Reindl, W.(1);Thomann, A.K.(1);
(1)Medical Faculty Mannheim-Heidelberg University, Department of Medicine II, Mannheim, Germany;(2)Hannover Medical School, Department of Gastroenterology- Hepatology- Infectious Diseases and Endocrinology, Hannover, Germany;(3)University Hospital rechts der Isar, Department of Internal Medicine II, Munich, Germany;
P0675: Ultrasonographic assessment of response in hospitalized patients with acute severe ulcerative colitisECCO'25Year: 2025
Authors: Arora, U.(1)*;Kandasamy, D.(2);Verma, M.(1);Madan, D.(1);Singh, M.(1);Narang, H.(1);Goyal, M.(1);Mubunnu, M.(1);Panwar, R.(3);Dash, N.R.(3);Goyal, A.(2);Sharma, R.(2);Ahuja, V.(1);Kedia, S.(1);
(1)All India Institute of Medical Sciences, Gastroenterology and Human Nutrition, New Delhi, India;(2)All India Institute of Medical Sciences, Radiodiagnosis and intervention radiology, New Delhi, India;(3)All India Institute of Medical Sciences, Gastrointestinal surgery and liver transplantation, New Delhi, India;
P0676: Inborn Errors of Immunity Associated with Inflammatory Bowel Disease at a Tertiary Care CentreECCO'25Year: 2025
Authors: Albadawi, N.(1)*;Almuhaya, H.(1);Alrossais, N.(1);Binzuman, G.(2);Alhaddab, N.(2);Aljefri, N.(3);Alsehaim, K.(3);Alshaikh, A.(2);Alsoqair, S.(4);Arnaout, R.(3);Alshareef, S.(3);Albawardy, B.(1);Alsohaibani, F.(1);
(1)King Faisal Specialist Hospital & Research Centre, Department of Internal medicine- Division of Gastroenterology and hepatology, Riyadh, Saudi Arabia;(2)King Faisal Specialist Hospital & Research Centre, Department of Internal Medicine, Riyadh, Saudi Arabia;(3)King Faisal Specialist Hospital & Research Centre, Department of Internal medicine- Division of Allergy and immunology, Riyadh, Saudi Arabia;(4)Alfaisal University, College of Medicine, Riyadh, Saudi Arabia;
P0677: Population-Based Analysis of 30-Day Postoperative Course in Crohn’s Disease Patients Undergoing Primary Bowel ResectionECCO'25Year: 2025
Authors: Poulsen, A.(1)*;Damsgaard Wewer, M.(2,3);Lin, V.A.(4);Rønne Pachler, F.(5);Verlo, K.A.(2);Rasmussen, J.(6);Søe Riis Jespersen, H.(2);Surnecheva, E.(7);Christiansen, D.(6);Holm Hansen, E.(8);Møller Nordestgaard, R.L.(2);Aydemir, N.(6);Dige Ovesen, P.(5);Filtenborg Brandt, C.(1);Gögenur, I.(4);Burisch, J.(2,3);Seidelin, J.(1);
(1)University Hospital of Copenhagen- Rigshospitalet, Department of Digestive Diseases- Transplantation and General Surgery- Section for IBD, Copenhagen, Denmark;(2)Copenhagen University Hospital - Amager and Hvidovre, Gastrounit - Medical Section, Hvidovre, Denmark;(3)Copenhagen University Hospital- Amager and Hvidovre, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(4)Zealand University Hospital- Køge, Center for Surgical Science, Koege, Denmark;(5)Copenhagen University Hospital- Herlev and Gentofte, Department of Gastroenterology and Hepatology, Herlev, Denmark;(6)Zealand University Hospital Koege, Department of Medical Gastroenterology, Koege, Denmark;(7)Copenhagen University Hospital- Bispebjerg and Frederiksberg, Digestive Disease Center, Copenhagen, Denmark;(8)HospitalCopenhagen University Hospital – North Zealand, Department of Gastroenterology, Frederikssund, Denmark;
P0678: Iron deficiency, with or without anaemia, in Inflammatory Bowel Disease remains an undermanaged issue: Crohn’s Colitis Cure Data Insights ProgramECCO'25Year: 2025
Authors: Pinnuck, B.(1)*;Su, W.K.(2,3);Wilson, W.(4);Pipicella, J.(3,5,6);Ng, W.(2,6);Antoniades, S.(7);Walker, G.(8,9,10);Forbes, A.(11);Dutt, S.(12,13);Lynch, K.(1,14);Connor, S.J.(2,6,15,16);Andrews, J.M.(17,18);
(1)Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia;(2)Liverpool Hospital, Gastroenterology and Hepatology, Sydney, Australia;(3)The Ingham Institute for Applied Medical Research- Gastroenterology- Hepatology and Inflammatory Bowel Disease Research Group, Gastroenterology and Hepatology, Sydney, Australia;(4)South Australia Health, South Australia Health, Adelaide, Australia;(5)Crohn's Colitis Cure, Head of Operations, Sydney, Australia;(6)University of New South Wales, South West Sydney Clinical Campuses, Sydney, Australia;(7)St Vincent’s Public Hospital Sydney, Gastroenterology and Hepatology, Sydney, Australia;(8)Royal Brisbane and Women's Hospital, Gastroenterology and Hepatology, Brisbane, Australia;(9)QIMR Berghofer, Medical Research Institute, Brisbane, Australia;(10)University of Queensland, Faculty of Medicine, Brisbane, Australia;(11)University of Otago, Department of Medicine, Christchurch, New Zealand;(12)The Children’s Hospital at Westmead, Gastroenterology, Sydney, Australia;(13)The University of Sydney, Sydney School of Medicine- Faculty of Medicine and Health, Sydney, Australia;(14)University of Adelaide, Faculty of Health Sciences, Adelaide, Australia;(15)Crohn’s Colitis Cure, Board member, Sydney, Australia;(16)The Ingham Institute for Applied Medical Research, Gastroenterology and Hepatology, Sydney, Australia;(17)Crohn's Colitis Cure, Board member, Adelaide, Australia;(18)Central Adelaide Local Health Network, Gastroenterology and Hepatology, Adelaide, Australia;
P0679: Therapeutic Drug Monitoring of the Infliximab (anti-TNF) Level with Bedside Kit in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Gur, M.B.(1)*;Bakkaloglu, O.K.(2);Eskazan, T.(3);Akpinar, A.(3);Hatemi, A.İ.(3);Erzin, Y.Z.(3);Celik, A.F.(3);
(1)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey;(2)Kosuyolu High Specialization Education and Research Hospital, Gastroenterology, Istanbul, Turkey;(3)Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;
P0680: Upadacitanib in Inflammatory Bowel Disease: Evaluating the risk of neutropenia and impact of thiopurine exposureECCO'25Year: 2025
Authors: Sharpe, M.(1)*;Khose, S.(1);Fletcher, J.(1);Samanta, S.(1);
(1)Queen’s Hospital- Barking- Havering and Redbridge University Hospitals NHS Trust, Gastroenterology, London, United Kingdom;
1. NICE Guidance. Upadacitinib for treating moderately to severely active ulcerative colitis. Technology appraisal guidance.4 January 2023: TA856.
2. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542-550.
3. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase 3 clinical program. Arthritis Res Ther. 2019;21(1):282.
4. Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15,000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9
P0681: Filgotinib for active Ulcerative Colitis in clinical practice - Effective treatment at week 8 is associated with higher clinical remission and persistence rates at Week 52 -ECCO'25Year: 2025
Authors: Yamada, A.(1)*;Yokoyama, K.(1);Harada, Y.(1);Ito, T.(1);Horii, T.(1);Kanazawa, J.(1);Ikehara, H.(1);Kusano, C.(1);
(1)Kitasato University School of Medicine, Gastroenterology, Sagamihara, Japan;
P0682: Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study.ECCO'25Year: 2025
Authors: Ferreira, S.(1)*;Serafim Parra, R.(2);Yukie Sassaki, L.(3);Luz Parente, J.M.(4);Kurtz de Mello, M.(5);Andrade Chebli, L.(6);Luporini, R.L.(7);Tiburcio Alves Junior, A.J.(8);Firmino Nóbrega, F.J.(9);da Silva, B.C.(10);Miranda, E.F.(11);Botelho Quaresma, A.(12);Mattioli Nicollelli, G.(13);Galhardi Gasparini, R.(14);de Medeiros Dutra, R.(3);da Conceição da Silva, K.(15);Oliveira Magro , D.(16);Imbrizi, M.R.(16);Kibune Nagasako , C.(17);Féres, O.(18);de Almeida Troncon, L.E.(19);Kotze, P.G.(20);Fonseca Chebli, J.M.(21);
(1)Hospital das Clínicas- Ribeirão Preto Medical School, Medicine, Ribeirão Preto, Brazil;(2)Hospital das Clínicas - Ribeirão Preto Medical School, Surgery and Anatomy- Ribeirão Preto- São Paulo- Brazil., Ribeirão Preto, Brazil;(3)Medical School- Sao Paulo State University UNESP, Internal Medicine, Botucatu, Brazil;(4)Health Science Center, Division of Gastroenterology of the Medicine Course at Federal University of Piauí, Teresina, Brazil;(5)University of Vale do Itajaı´, Medicine, Itajaí, Brazil;(6)Division of Gastroenterology- Federal University of Juiz de Fora, Medicine, Juiz de Fora, Brazil;(7)Federal University of São Carlos UFSCar, Medicine, São Carlos, Brazil;(8)PUC-Campinas Medical School, Surgery, Campinas, Brazil;(9)Lauro Wanderley Hospital- Federal University of Paraíba, Gastroenterology, João Pessoa, Brazil;(10)Hospital da Bahia, Gastroenterology, Salvador, Brazil;(11)Pontificia Universidade Católica do Paraná PUCPR, Surgey, Curitiba, Brazil;(12)Universidade do Oeste de Santa Catarina UNOESC, Surgery, Joaçaba, Brazil;(13)Hospital de Clínicas da UFPR, Surgery, Curitiba, Brazil;(14)Sete - Specialized Medical Center, Sete - Specialized Medical Center, Marília, Brazil;(15)Hospital Universitário da Universidade Federal do Piauí, Medicine, Teresina, Brazil;(16)State University of Campinas UNICAMP, Surgery, Campinas, Brazil;(17)State University of Campinas UNICAMP, Medicine, Campinas, Brazil;(18)Ribeirão Preto Medical School- University of São Paulo, Surgery and Anatomy, Ribeirão Preto, Brazil;(19)Ribeirão Preto Medical School- University of São Paulo, Medicine, Ribeirão Preto, Brazil;(20)Pontificia Universidade Católica do Paraná PUCPR, Health Sciences Postgraduate Program, Curitiba, Brazil;(21)Division of Gastroenterology - Federal University of Juiz de Fora, Medicine, Juiz de Fora, Brazil;